Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as A01016
Ocriplasmin · 1 trial · 1 indication
VMA (adhesion of the vitreous gel to the retina in an abnormally strong manner) was determined by masked Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT) evaluation. Only one eye (study eye) was analyzed. Proportion of subjects is reported as a percentage.
| Arm | Type | Description |
|---|---|---|
| Ocriplasmin | EXPERIMENTAL | Ocriplasmin administered as a single intravitreal injection to the study eye at baseline |
| Sham injection | SHAM_COMPARATOR | Single sham injection to the study eye at baseline |
| Name | Type | Description |
|---|---|---|
| Ocriplasmin | DRUG | - |
| Sham injection | DRUG | - |
Inclusion Criteria: * Symptomatic vitreomacular adhesion (VMA) which, in the opinion of the Investigator, is related to decreased visual function; * Best corrected visual acuity (BCVA) of 20/25 or worse in the study eye; * BCVA of 20/800 or better in the non-study eye; * Provide written informed co...
Ocriplasmin is an investigational small molecule developed by Alcon Inc. (ticker ALC) for symptomatic vitreomacular adhesion, an eye condition in which the vitreous gel adheres abnormally to the macula. It is being studied as a pharmacological option in ophthalmology and has completed a Phase 3 clinical trial in Japan.
Ocriplasmin is being developed to treat symptomatic vitreomacular adhesion, a condition where the vitreous gel remains abnormally attached to the macula and causes symptoms. The clinical program targets adults aged 20 years and older with this diagnosis. It is investigational and has not been established as a marketed treatment.
Ocriplasmin targets laminin proteins, specifically LAMA1, LAMA2, LAMA3, LAMA4, LAMA5, and LAMB1. It is a hydrolytic enzyme, meaning it acts by breaking down these laminin substrates. Laminins are components of the extracellular matrix at the vitreoretinal interface, which is relevant to its proposed activity in vitreomacular adhesion.
Ocriplasmin is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor of the clinical program evaluating the drug in symptomatic vitreomacular adhesion. The compound is also identified by the ChEMBL ID CHEMBL2095222.
Ocriplasmin is in Phase 3 development for symptomatic vitreomacular adhesion. One Phase 3 trial has been completed, and no trials are currently active. The drug is investigational and is not described as approved by the FDA for this indication.
Ocriplasmin has been studied in the Phase 3 trial NCT01889251, titled A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion. That trial enrolled 251 participants in Japan, was randomized, double blind, and sham controlled, and has completed. No trials are currently active.